Pharmaceuticals, Biotechnology and Life Sciences
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.
BiondVax Pharmaceuticals got its patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate accepted in Australia.
The U.S. Food and Drug Administration Monday approved Dovato, two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
United Therapeutics Corporation Monday said that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.
Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid…
Indivior’s “Recover” study found that 75% of patients who had received 12 once-monthly doses of sublocade in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended. In this observational study, abstinence was defined as self-report confirmed by urine drug screen.
Mallinckrodt’s retrospective study has shown the effectiveness of Extracorporeal Photopheresis (ECP), as an adjunct to local standard therapy, in lung transplant recipients with Bronchiolitis Obliterans Syndrome (BOS).
Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in…
Belgian Oxurion has enrolled 70 patients for Phase 2 testing of its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).